Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Wu, Xinqi, Giobbie-Hurder, Anita, Connolly, Erin M., Li, Jingjing, Liao, Xiaoyun, Severgnini, Mariano, Zhou, Jun, Rodig, Scott, Hodi, F. Stephen
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5993498/
https://ncbi.nlm.nih.gov/pubmed/29900046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1440930
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge